By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Rigel Pharmaceuticals, Inc. 

1180 Veterans Boulevard

South San Francisco  California  94080  U.S.A.
Phone: 650-624-1100 Fax: 650-624-1101

Rigel's. Rigel's mission is to become a source of novel, small-molecule drugs to address large, unmet medical needs. We have initiated four development programs: asthma/allergy, hepatitis C, rheumatoid arthritis and oncology. Our first two product candidates, R112 for allergic rhinitis and R803 for hepatitis C, are in clinical testing. We expect to begin a clinical trial of R406 for the treatment of rheumatoid arthritis by the end of 2004, to be followed by initiation of clinical trials with additional product candidates for indications in oncology and asthma. Our approach to drug discovery is based on advanced, proprietary techniques that allow us to identify targets with a demonstrable role in a disease pathway and to screen efficiently for those targets that are likely to be amenable to drug modulation. We believe that this approach to drug discovery will enable us to commence clinical trials with one to two lead compounds each year. Our research efforts are focused in the areas of immunology/inflammation, virology and oncology.

Last Updated: 10-18-04

Key Statistics

Ownership: Public

Web Site: Rigel
Employees: 135
Symbol: RIGL


Drug Discovery

Company News
Rigel (RIGL) Welcomes Brian Kotzin, M.D. To Board Of Directors 8/25/2017 6:50:43 AM
Rigel (RIGL) Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4) 8/21/2017 6:06:54 AM
Rigel (RIGL) Announces Second Quarter 2017 Financial Results And Provides Company Update 8/2/2017 12:29:13 PM
Rigel (RIGL) Announces Conference Call And Webcast To Report Second Quarter 2017 Financial Results 7/25/2017 11:39:21 AM
FDA Accepts Rigel (RIGL)'s New Drug Application For TAVALISSE (Fostamatinib Disodium) For The Treatment Of Chronic ITP 6/19/2017 6:44:03 AM
Rigel (RIGL): Tavalisse NDA Will Be A Game-Changer 5/26/2017 6:15:38 AM
Rigel (RIGL) Announces First Quarter 2017 Financial Results And Provides Company Update 5/3/2017 10:12:35 AM
Rigel (RIGL) Announces Tavalisse As Proprietary Name For Fostamatinib In The United States 4/27/2017 11:27:27 AM
Rigel (RIGL) Announces Conference Call And Webcast To Report First Quarter 2017 Financial Results 4/25/2017 10:03:33 AM
Rigel (RIGL) Submits New Drug Application To FDA For Fostamatinib In Chronic ITP 4/18/2017 7:22:45 AM